| Not Yet Recruiting | Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) NCT06811454 | Case Comprehensive Cancer Center | N/A |
| Recruiting | [18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer NCT07314073 | Asan Medical Center | Phase 2 |
| Not Yet Recruiting | SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response NCT07129187 | Chuan Wang | Phase 2 |
| Recruiting | A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. NCT07095114 | Barbara Ann Karmanos Cancer Institute | N/A |
| Recruiting | A Study of Revaree Plus in People With Breast Cancer NCT07042581 | Memorial Sloan Kettering Cancer Center | Phase 4 |
| Withdrawn | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 | Travera Inc | — |
| Recruiting | Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy NCT06926543 | Dr. Tabassum Wadasadawala | Phase 3 |
| Recruiting | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) NCT05512364 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Recruiting | Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment NCT06087120 | Gene Solutions | — |
| Recruiting | TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Pat NCT05535192 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Improving Exercise Capacity With a Tailored Physical Activity Intervention NCT05595577 | Wake Forest University Health Sciences | N/A |
| Completed | Ask Questions (ASQ):Implementation of a Communication Intervention NCT05025748 | Barbara Ann Karmanos Cancer Institute | N/A |
| Active Not Recruiting | Niraparib + Dostarlimab In BRCA Mutated Breast Cancer NCT04584255 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hor NCT04553770 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Researching the Effect of Exercise on Cancer NCT04589468 | Memorial Sloan Kettering Cancer Center | N/A |
| Active Not Recruiting | MARGetuximab Or Trastuzumab (MARGOT) NCT04425018 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer NCT01907529 | Hebei Medical University Fourth Hospital | Phase 2 / Phase 3 |
| Withdrawn | Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Can NCT03091842 | University of Southern California | N/A |
| Active Not Recruiting | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectabl NCT03971409 | Laura Huppert, MD, BA | Phase 2 |
| Active Not Recruiting | Acupuncture Pilot Study for Cancer-related Cognitive Function NCT04007770 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Living Well After Breast Surgery NCT03834532 | University of Texas at Austin | N/A |
| Terminated | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen R NCT03566485 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer NCT03387553 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Completed | Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partn NCT03112668 | Rutgers, The State University of New Jersey | N/A |
| Completed | 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients W NCT03364348 | George W. Sledge Jr. | Phase 1 |
| Completed | Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy NCT03102866 | Ohio State University Comprehensive Cancer Center | N/A |
| Terminated | Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors NCT03284346 | University of Southern California | N/A |
| Terminated | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage NCT03128619 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resi NCT02860000 | Mayo Clinic | Phase 2 |
| Completed | Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery NCT03113825 | Avelas Biosciences, Inc. | Phase 2 |
| Unknown | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hor NCT03044730 | Northwestern University | Phase 2 |
| Completed | Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer NCT03139435 | Wake Forest University Health Sciences | N/A |
| Completed | Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative NCT02780401 | University of Washington | Phase 1 |
| Active Not Recruiting | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy NCT02445391 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Completed | Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors NCT03198286 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | N/A |
| Active Not Recruiting | Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer NCT02157051 | University of Washington | Phase 1 |
| Active Not Recruiting | T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA NCT02326974 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer NCT02115152 | Guangxi Medical University | Phase 2 |
| Completed | A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients NCT02129686 | Dana-Farber Cancer Institute | N/A |
| Terminated | Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin NCT02096588 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Brea NCT01750073 | University of Nebraska | Phase 2 |
| Terminated | A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer NCT01194427 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer NCT01431196 | Clinica Universidad de Navarra, Universidad de Navarra | Phase 2 |
| Completed | Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer NCT00262834 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Capecitabine in Women With Operable Breast Cancer NCT00148720 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors NCT01831076 | University of Colorado, Denver | Phase 2 |
| Completed | Preoperative Herceptin and Navelbine for Breast Cancer NCT00148681 | Dana-Farber Cancer Institute | Phase 2 |